Catalog11 refs
Mazdutide
Metabolicglp1Research use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
CirculationSkin
Overview
Mazdutide (LY3305677/IBI362) is a dual GLP-1 and glucagon receptor agonist developed through a collaboration between Eli Lilly and Innovent Biologics. By activating both GLP-1 and glucagon receptors, it combines the appetite-suppressing and insulin-sensitizing effects of GLP-1 agonism with the energy expenditure-boosting and fat-mobilizing effects of glucagon agonism. Phase 3 trials in China have shown significant weight loss and metabolic improvements.
Primary Uses
weight loss
metabolic improvements
liver fat reduction (MASH/NAFLD)
type 2 diabetes
Obesity and diabetes trials
GLP-1/glucagon dual-agonist pharmacology
Weight-loss research
NAFLD/metabolic disease studies
Type 2 diabetes management
Diabetes-associated cognitive dysfunction
Protocol Reference
Dose
1-6mg weekly (titrated)
Frequency
Once Weekly, Same Day Each Week
Half-life
Long-acting; roughly supports once-weekly dosing
Route
Subcutaneous
Evidence
Phase 3 trials
Research References· 17
Research Models
Human
Also in Metabolic